Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	24.02	0.88	-1,032	175.07	528.45
Depreciation & Amortization	1.88	2.01	1.58	1.42	1.52
Stock-Based Compensation	17.25	29.85	32.01	27.05	22.28
Other Adjustments	44.25	71.63	1,170	67.41	-310.09
Change in Receivables	35.15	47.24	0.92	7.99	7.71
Changes in Accounts Payable	6.2	-20.21	12.58	-1.12	-2.64
Changes in Accrued Expenses	-4.11	-14.65	-5.88	-10.64	14
Changes in Other Operating Activities	2.41	-13.2	3.85	14.46	-1.46
Operating Cash Flow	127.04	103.55	183.43	273.76	261.9
Operating Cash Flow Growth	22.69%	-43.55%	-33.00%	4.53%	55.12%
Capital Expenditures	-0.03	-0.14	-0.27	-0.14	-0.27
Payments for Business Acquisitions	-	-	-1,026	-	-
Investing Cash Flow	-0.03	-0.14	-1,026	-0.14	-0.27
Short-Term Debt Issued	-	150	400	-	-
Short-Term Debt Repaid	-	-65	-100	-	-
Net Short-Term Debt Issued (Repaid)	-	85	300	-	-
Long-Term Debt Repaid	-	-200	-	-120.7	-
Net Long-Term Debt Issued (Repaid)	-	-200	-	-120.7	-
Issuance of Common Stock	0.22	11.01	6.36	9.54	19.58
Repurchase of Common Stock	-	-0.74	-	-126.39	-24.13
Net Common Stock Issued (Repurchased)	0.22	10.28	6.36	-116.85	-4.55
Other Financing Activities	-	-2.25	-29.2	-	-
Financing Cash Flow	0.22	-106.97	277.16	-237.55	-4.55
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.33	-0.03	-0.05	-	-
Net Cash Flow	126.9	-3.6	-565.78	36.07	257.08
Free Cash Flow	127.01	103.41	183.15	273.63	261.63
Free Cash Flow Growth	22.82%	-43.54%	-33.06%	4.58%	56.67%
FCF Margin	42.89%	29.43%	41.37%	66.64%	63.23%
Free Cash Flow Per Share	0.78	0.65	1.18	1.47	1.59
Levered Free Cash Flow	30.37	-160.31	-1,722	233.42	1,068
Unlevered Free Cash Flow	169.57	138.81	-850.32	331.04	-136

Updated Feb 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q